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Abstract
The survival of axotomized RGCs was increased by intravitreal NT-4:5 given by repeated injections or osmotic minipumps, but
the effects were less complete than predicted. Compared to a single injection of the neurotrophin on day 0, second injections on
days 3 or 7 only sustained an additional 10–20% of the RGCs on day 10. Minipumps augmented RGC survival up to 4-fold (50%)
at 2 weeks but most RGCs were lost by 1 month. Thus, specific neurotrophins can rescue many RGCs soon after injury but
long-term neuronal survival may require a better understanding of changes in neurotrophin receptors and interactions with other
molecules. © 1998 Elsevier Science Ltd. All rights reserved.
Keywords: Retinal ganglion cells; Axotomy; Neurotrophin-4:5; Apoptosis; Cell death; Adult rats
1. Introduction
After axotomy near the eye, retinal ganglion cell
(RGC) death by apoptosis begins on day 4, and leads
to the rapid loss of most RGCs: only 50% remain on
day 7, 25% on day 10, and less than 10% on day 14 [2].
Single intravitreal injections of BDNF [18] or NT-4:5
[22] on the day of axotomy delay the onset of RGC
death by approximately 3 days but the effect is not
maintained; all of the neurotrophin-treated RGCs sur-
vive to day 7 (100%), decreasing to approximately 60%
by day 10, and to 20–40% by day 14. Additional
examples of the transientness of the effects of BDNF or
NT-4:5 on the survival of injured neurons have been
documented in neonatal animals after axotomy of
RGCs [6] or spinal motor neurons [8,23,26].
The massive early loss of RGCs that follows optic
nerve (ON) transection is also delayed by the attach-
ment of PN grafts [28] or by the application of periph-
eral nerve extracts [19]. The effect of attaching PN
grafts, which presumably provide injured RGCs with
trophic molecules critical for survival, lasts longer than
the effect of a single neurotrophin administration, but
also declines between 1 and 3 months. On the other
hand, the reconnection of RGCs with their normal
targets in the superior colliculus (SC) may assure the
survival of these neurons. Indeed, when the retina and
the SC are reconnected by a peripheral nerve (PN)
graft, the numbers of regenerated RGC axonal termi-
nals remains stable between 4–6 and 8–10 months after
axotomy and graft placement [4]. Thus, axotomy-in-
duced RGC loss appears to be preventable. Moreover,
most of these cells might persist throughout the life of
the animal if the survival of the injured RGCs could be
maintained until their axons were allowed to regenerate
and form synapses in the SC.
The aim of the present experiments was to determine
if a more prolonged exposure of axotomized RGCs to
NT-4:5, a neurotrophin that shares many homologies
with BDNF [3,12,14], would lengthen their survival
beyond the few days possible with single injections.
Because their numbers can be precisely analysed, RGCs
are a particularly useful neuronal population in which
to study the effects of repeated or prolonged neuro-
trophin administration.
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2. Methods
2.1. Surgical procedures
Surgical procedures were performed in adult female
Sprague-Dawley rats (180–200 g) anesthetized with in-
traperitoneal chloral hydrate (7%) in accordance with
the principles outlined in ‘‘The Guide to the Care and
Use of Experimental Animals’’ of the Canadian Coun-
cil on Animal Care. Prior to experimental manipula-
tions, Fluorogold® [24] was applied to the surface of
both superior colliculi to label the cell bodies of RGCs
by retrograde transport [2]. One week later, the left
optic nerve (ON) was transected with microscissors,
leaving a 0.5-mm stump attached to the globe. Preser-
vation of the retinal blood supply was confirmed by
microscopic examination of the retina through the di-
lated pupil.
2.2. Administration of NT-4:5
To determine the effect of single injections, 5 ml of
human recombinant NT-4:5 (E. coli-derived; provided
by Regeneron Pharmaceuticals, Inc.) were injected
slowly into the vitreous chamber of the eye at the time
of ON transection. The tip of the needle was inserted
into the vitreous chamber by a posterior approach
through the sclera and retina at a distance of approxi-
mately 3 mm from the ON into the dorso-temporal
quadrant (Fig. 1). After the injection, the hole through
the sclera was sealed with Histoacryl tissue glue. Con-
trol rats received an intravitreal injection of 5 ml of
vehicle (phosphate-buffered saline, PBS).
In groups of four to six rats, 3 mg of NT-4:5 in 5 ml
PBS or 5 ml of PBS alone were given in the following
sets of experiments: (i) single injections at the time of
ON transection with measurement of RGC densities 7,
10, 14, 21 and 28 days later; (ii) single injections 7 or 3
days before, or 3 or 6 days after, ON transection with
determinations of RGC densities 10 days after ON
transection (day 10); (iii) a first injection at the time of
ON transection and a second injection on day 3 or day
7 with measurement of RGC densities on day 10 or day
14.
To determine the effect of prolonged neurotrophin
administration on RGC survival, NT-4:5 was delivered
to the vitreous chamber of the eye from an osmotic
mini-pump (Alzet c2002) filled with NT-4:5 (0.1 mg:
ml) or PBS and placed in a subcutaneous pocket. The
osmotic mini-pump delivered either NT-4:5 (n8) or
PBS (n9) at approximate rates of 0.5 ml:h for 14
days. In other rats, the pumping rate was reduced by
50% to deliver either NT-4:5 (n4) or PBS (n3) at
approximately 0.25 ml:h for 28 days.
2.3. Tissue processing
At the end of the experimental period, the rats were
deeply anesthetized with chloral hydrate (900 mg:kg)
and perfused through the heart with 50–100 ml of 0.9%
normal saline followed by 200–300 ml of 4%
paraformaldehyde in 0.1 M phosphate buffer. The left
(experimental) and right (internal control) eyes were
removed and the retinas flat-mounted.
2.4. Quantitation of RGC sur6i6al
Using a fluorescence microscope, the number of sur-
viving RGCs in experimental and control retinas were
determined by counting the number of Fluorogold®-la-
belled neurons in three standard areas of each retinal
quadrant at 1, 2 and 3 mm from the optic disc, for a
total area of 0.965 mm2 [2,29]. RGC survival data from
each group of animals are presented as the mean densi-
ties (RGCs:mm2) and standard deviations (mean9
S.D.). The results were analyzed with the SigmaStat
program, as previously described [18].
3. Results
3.1. Optimum dose of NT-4:5
To determine the optimum amount of NT-4:5 to
enhance RGC survival, 5 ml of NT-4:5 in doses ranging
from 0 to 0.84 mg:ml were administered at the time of
axotomy (day 0) in groups of four to six rats. Increas-
ing amounts of NT-4:5 resulted in dose-dependent in-
crements in RGC survival that peaked at 3 mg. A higher
dose (4.2 mg) did not further increase RGC survival 10
days after axotomy (Fig. 2).
Fig. 1. Diagram of the surgical procedure for optic nerve (ON)
transection and administration of NT-4:5 or control vehicle (0.1 M
phosphate-buffered saline) into the vitreous space of adult rats. One
week after the RGCs were labelled with Fluorogold retrogradely
transported from the superior colliculus, 5 ml of NT-4:5 in PBS or 5
ml of PBS were given as a single injection. Delivery of the neuro-
trophin or vehicle by this route avoided injury to the anterior
structures of the eye such as the lens, iris and ciliary body.
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Fig. 2. NT-4:5 dose–response analysis indicating the densities of
retinal ganglion cells (RGCs) (mean9S.D.; n4–6 retinas per
group) 10 days after ON transection near the eye and single intravit-
real injections of NT-4:5 (solid bars) or vehicle alone (hatched bar).
NT-4:5 had its most potent survival effect when 3.0 mg (0.6 mg:ml) was
given; there was no additional increase in survival when 4.2 mg of
NT-4:5 was given. When only 0.05 mg of NT-4:5 was given, RGC
survival did not differ significantly from that after a control injection.
administration of PBS. However, when NT-4:5 was
administered at 3 days before or 3 days after axotomy,
nearly 50% of the RGCs survived (Fig. 5). Although
the effect was still statistically significant, fewer RGCs
survived when the NT-4:5 was given 7 days before
(33%) or 6 days after (42.6%). These results suggest that
the injury to the RGCs had not blocked the capacity of
most of these neurons to respond to the neurotrophin.
3.4. Prolonged neurotrophin administration
With control osmotic minipumps that contained
PBS, the density of surviving RGCs at 2 weeks was
271997 (mean9S.D.) or 12% of the original RGC
population compared to 114930 for the retinas with-
out minipumps (Fig. 6). The RGC densities for individ-
ual retinas from the groups of animals treated with
NT-4:5 via the osmotic mini-pumps (Fig. 6) fell into
two ranges: in three of the eight animals with NT-4:5
pumps for 2 weeks, RGC densities were 7 or more
standard deviations beyond the mean for the PBS-
treated group. In these three retinas, nearly 50% of the
normal RGCs were preserved 2 weeks after injury. In
the other five retinas, RGC densities were within 3
standard deviations of this mean.
At 4 weeks, the mean RGC density in the PBS-
treated retinas was 91933 (4%). In two of the four
NT-4:5-treated retinas, the RGC densities were more
than 10 standard deviations above the mean for the
control retinas; RGC densities in the other two retinas
were not significantly different from the mean for the
control retinas (Fig. 6).
Thus, in some treated retinas, the continuous infu-
sion of NT-4:5 had a substantial effect on RGC sur-
vival. The variability of the responses observed in these
animals may have been due to technical difficulties in
maintaining a patent cannula within the small vitreous
chamber of the rat eye, a possibility that could not be
independently assessed. Vehicle-containing minipumps
slightly increased this survival (Fig. 6), suggesting that
injury-related trophic cytokines [30] were released by
the intravitreal placement of the canula.
3.5. RGC sur6i6al after two injections of NT-4:5
Second injections of NT-4:5 on day 3 only increased
the density of surviving RGCs by approximately 10%
of the RGC population (Fig. 7), an effect that was not
statistically significant from that of single injections on
day 0 (14849223 vs. 1371923 cells:mm2 ; P\0.05,
t-test). When the second injections were given on day 7
(Figs. 4 and 7), 16% more RGCs survived on day 10
(17239172 vs. 1371923; P0.002, Mann-Whitney
rank sum test) and 18% more on day 14 (796981 vs.
391952; PB0.001, t-test) but the rate of RGC loss
did not change (Fig. 4).
3.2. Single NT-4:5 injection
In uninjured retinas, the density of FG-labelled
RGCs was 2215969:mm2. As previously reported [2],
RGC numbers were maintained for the first 4 days after
ON transection but decreased rapidly over the next
week (Fig. 3). Less than 10% of the RGCs (114912)
survived by 2 weeks and, by 28 days, fewer than 2% of
these neurons were still present (Fig. 4).
After administration of NT-4:5 at the time of axo-
tomy, RGC densities remained normal for 7 days (Figs.
3 and 4). Thereafter, the rate of RGC loss parallelled
that of the untreated retinas. By day 14, RGC survival
in the NT-4:5-treated retinas remained statistically
greater (391952:mm2; 17.7%) than after a PBS injec-
tion (181951; 8.2%) or axotomy alone (114912;
5.1%). By 21 days, when only 4.6% of the RGCs
survived, the effect of the single administration of NT-
4:5 was completely dissipated.
3.3. NT-4:5 administered before or after axotomy
The optimum amount of NT-4:5 (3 mg) or an equal
volume of PBS (5 ml) was administered before (3 or 7
days) or after axotomy (3 or 6 days). RGC survival in
these retinas at 10 days was compared to that seen
when NT-4:5 was administered at the same time as the
ON transection. The greatest survival effect was ob-
served when NT-4:5 was administered at the time of
axotomy (62%), compared to (22.9%) following the
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Fig. 3. Fluorogold-labelled RGCs in segments of flat-mounted retinas photographed 1 mm from the optic nerve head. (A) Intact retina. The
punctate Fluorogold fluorescence labels the perikarya and proximal dendrites of RGCs. (B) Retina 7 days after optic nerve (ON) transection
without treatment. The number of labelled RGCs is markedly decreased. The elongated or irregularly shaped cells that are intensely fluorescent
are microglia that phagocytosed Fluorogold from degenerating RGCs. (C) Retina 7 days after ON transection and a single injection of NT-4:5.
The number of RGCs appears to be similar to that of the intact retina and microglia are rarely seen. Bar50 mm.
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Fig. 4. Retinal ganglion cell (RGC) densities (mean9S.D.) after ON
transection and no treatment (open triangles) and after a single
injection of NT-4:5 on day 0 (filled circles). NT-4:5 delayed the onset
of RGC death by 3 days. With a second injection of NT-4:5 on day
7 (filled squares), 16% more RGCs survived on day 10. With both the
single and double injection, the subsequent rate of cell loss was
similar to that observed in the untreated retinas.
Fig. 6. Prolonged NT-4:5 administration. Densities of RGCs from
individual animals after administration of NT-4:5 at a concentration
of 0.1 mg (filled circles) or PBS (open circles) by osmotic mini-pumps
for 14 days (0.5 ml:h) or 28 days (0.25 ml:h) compared to ON cut only
(open triangles). The bars depict the mean RGC density for the
control groups that were normally distributed. In three animals with
NT-4:5 pumps for 2 weeks, and in two with the pumps for 4 weeks,
the density of surviving RGCs was more than 7 standard deviations
beyond the mean for the PBS-treated groups.
4. Discussion
It is well known that the administration of specific
neurotrophins can prevent the acute loss of many
classes of injured neurons in vivo [1]. In the rat eye, for
example, the death of axotomized RGCs, nearly all of
which express TrkB [13], can be delayed for approxi-
mately 3 days by intravitreal injections of BDNF or
NT-4:5 [18,22]. Subsequently, the rates of RGC loss
paralleled those observed in the untreated eyes.
In the present experiments, we investigated the sur-
vival of axotomized RGCs after administration of NT-
Fig. 7. Survival after two injections of NT-4:5. Retinal ganglion cell
(RGC) densities (mean9S.D.; n3–6 per group) 10 and 14 days
after optic nerve transection and an intravitreal injection of PBS
(hatched bars) or NT-4:5 treatment (solid bars). The NT-4:5 was
given as a single injection on day 0, or as two injections on day 0 and
day 7. A second injection of NT-4:5 on day 3 did not enhance RGC
survival. If the second injection of NT-4:5 was delayed until day 7,
there was a significant increase in the number of injured RGCs that
survived until day 10 or day 14.
Fig. 5. Retinal ganglion cell (RGC) survival 10 days after ON
transection near the eye and a single intravitreal injection of NT-4:5
(solid bars) or PBS (hatched bars) at the time of, before, or after
axotomy. At all times, the RGC densities were significantly greater in
the NT-4:5-treated retinas than in the PBS-treated retinas. There were
no significant differences in RGC densities among the PBS-treated
groups. The greatest mean survival occurred when NT-4:5 was given
at the time of axotomy.
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4:5 to determine if a more prolonged exposure of the
retina to this TrkB ligand would significantly extend the
survival of these injured CNS neurons beyond the few
days possible with single injections. Because intraven-
tricular administration of another neurotrophin, nerve
growth factor (NGF), appeared to prevent the loss of
all basal forebrain neurons after fimbria-fornix lesions
for periods of 2 or 4 weeks (e.g. Refs. [9,21,32]), we first
used osmotic minipumps to deliver NT-4:5 intravitre-
ally in adult rats in which one ON had been transected.
It was anticipated that this approach would extend the
early effects of a single intravitreal injection and pro-
long the viability of nearly all the axotomized RGCs
for more than 3 days. However, the administration of
NT-4:5 by osmotic minipump only augmented the pro-
portions of injured RGCs that survived axotomy to a
maximum of 50% of the RGC population at 2 weeks
and 30% at 4 weeks. Although this level of survival was
substantially greater than the 5 and 3% of the axoto-
mized RGCs that survived at 2 and 4 weeks with no
treatment, the prolonged administration with the
minipumps failed to sustain most of the neurons at 2 or
4 weeks, as would have been expected if the response of
the axotomized RGCs to NT-4:5 had been similar to
that of injured cholinergic CNS neurons to NGF.
These experiments did not reveal whether the failure
to obtain greater RGC survival was due to limited
neurotrophin availability or to changes in neuronal
responsiveness because the amount and duration of
NT-4:5 delivery with the minipumps could not be de-
termined. To address these issues more directly, we
compared the effect of single and double intravitreal
injections of NT-4:5. Since the loss of 50% of the RGC
population by 7 days after ON transection [2] can be
prevented by a single intravitreal injection of NT-4:5 or
BDNF on the day of axotomy (day 0), it was predicted
that a second injection would extend the effects of
NT-4:5 and preserve all RGCs for at least an additional
3 days (i.e. until day 10). However, when such second
injections were given on day 3 or day 7, 78% or less of
the RGC population survived on day 10. Thus, the
predicted effect of the second injection of neurotrophin
fell short by approximately 22% of the RGC popula-
tion. This was a substantial difference between the
predicted and actual RGC survival; 38% of the RGC
population die between day 7 and day 10 after the
single injection of NT-4:5, so the second injection failed
to rescue approximately 60% of the neurons at risk.
4.1. Possible explanations
Although the temporary effects of single injections of
BDNF [18] or NT-4:5 could have been due to a limited
availability of the neurotrophin, the failure of the sec-
ond injections to achieve the same level of short-term
survival predicted by the first injection suggests that
mechanisms other than neurotrophin availability were
involved. This possibility is also supported by the re-
sults of other experiments in which a more prolonged
intraretinal expression of the BDNF gene by the intro-
duction of an adenoviral vector into Mu¨ller glial cells
also prevented the early loss of RGCs but failed to
increase the number of RGCs that survived 16 days
after axotomy, in a pattern of rescue that was similar to
that observed after a single injection of NT-4:5 or
BDNF protein [7].
4.2. Receptor mechanisms
Possible explanations for this inability of these two
neurotrophins to sustain survival of an injured popula-
tion of Trk-B-expressing neurons beyond a few days are
suggested by the results of in vitro experiments by other
investigators. Exposure of hippocampal or cortical neu-
rons to BDNF or NT-4:5 causes the down-regulation
of trkB mRNA and protein [10,15]. In addition, the
prolonged exposure of responsive neurons to BDNF
down-regulates the stimulative effects of the subsequent
administration of BDNF or NT-3 on tyrosine phospho-
rylation [15] or phosphatidylinositol hydrolysis [31],
and the intraventricular administration of BDNF tran-
siently abolishes the injury-induced up-regulation of
BDNF mRNA within neurons of the dentate gyrus
[27]. In contrast, NGF has a positive regulatory effect
on its TrkA receptor [11,16,17]. Such differences in the
responses of TrkA and TrkB to their ligands could
explain the reduced effect observed in vivo after pro-
longed administration of NT-4:5 in the present experi-
ments, which, to our knowledge, are the only
experiments where the effect of repeated or prolonged
administration of BDNF or NT-4:5 alone on neuronal
survival was studied for more than 1 week after injury
in adult animals.
4.3. Other possibilities
When the ON is transected in transgenic mice that
overexpress the anti-apoptotic molecule, Bcl-2, approxi-
mately 65% of the axotomized RGCs survive for at
least 3 months [5]. Furthermore, the long-term survival
of neonatal RGCs is only possible in vitro [20] or
during development [25] if multiple trophic factors are
given and intracellular cAMP is augmented. It is also
possible that more prolonged survival of axotomized
neurons will be possible when there is a better under
standing of other molecules, activity-related processes
and receptor mechanisms involved in cell survival.
In summary, our studies indicate that the administra-
tion of additional neurotrophin can prolong the short-
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term survival of all of the injured RGCs for 3 days
beyond the time of onset of post-axotomy apoptosis.
However, neither these studies in the retina nor, to our
knowledge, any other in vivo studies have documented
quantitatively unequivocal examples of a prolonged
survival of an entire population of injured neurons
treated with BDNF or NT4:5. In vitro studies by other
investigators suggest that the diminishing effectiveness
of providing additional neurotrophins, such as BDNF,
is due to altered neuronal responsiveness. It is also
possible that the administration of several trophic
molecules will permit the more prolonged survival of
injured RGCs. Finally, because the determinants of
acute and protracted cell death may be different, it
remains to be proven that prolonged neurotrophin ad-
ministration can protect injured neurons indefinitely.
Nevertheless, it is evident that the use of the appropri-
ate trophic molecules is an effective tool to promote the
short-term survival of acutely injured neurons.
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